Up-regulation of transcriptional factor E2F1 in papillary and anaplastic thyroid cancers

Journal of Human Genetics

Volumn 49, Issue 6, 2004, Pages 312-318

  Onda, Masamitsu ^a   Nagai, Hisaki ^a   Yoshida, Akira ^b   Miyamoto, Shizuyo ^a   Asaka, Shin Ichi ^a   Akaishi, Junko ^a   Takatsu, Keisuke ^a   Nagahama, Mitsuji ^c   Ito, Kouichi ^c   Shimizu, Kazuo ^a   Emi, Mitsuru ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b KANAGAWA CANCER CENTER   (Japan)

^c ITO HOSPITAL   (Japan)

Author keywords

Anaplastic thyroid cancer; E2F gene family; Immunohistochemistry; mRNA expression; Papillary thyroid cancer

Indexed keywords

MESSENGER RNA; TRANSCRIPTION FACTOR E2F1; VIRUS PROTEIN; CELL CYCLE PROTEIN; COMPLEMENTARY DNA; DNA BINDING PROTEIN; E2F1 PROTEIN, HUMAN; E2F4 PROTEIN, HUMAN; PRIMER DNA; RETINOBLASTOMA PROTEIN; RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR E2F; TRANSCRIPTION FACTOR E2F4;

ADULT; ANAPLASTIC CARCINOMA; ARTICLE; CARCINOGENESIS; CELL CYCLE; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MULTIGENE FAMILY; NUCLEOTIDE SEQUENCE; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THYROID PAPILLARY CARCINOMA; THYROID UNDIFFERENTIATED CARCINOMA; UPREGULATION; BIOSYNTHESIS; CARCINOMA; CHEMISTRY; GENETICS; METABOLISM; MIDDLE AGED; PAPILLARY CARCINOMA; SIGNAL TRANSDUCTION; THYROID TUMOR; TUMOR CELL LINE;

ADENOVIRIDAE;

ADULT; CARCINOMA; CARCINOMA, PAPILLARY; CELL CYCLE PROTEINS; CELL DIFFERENTIATION; CELL LINE, TUMOR; DNA PRIMERS; DNA, COMPLEMENTARY; DNA-BINDING PROTEINS; E2F TRANSCRIPTION FACTORS; E2F1 TRANSCRIPTION FACTOR; E2F4 TRANSCRIPTION FACTOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; RETINOBLASTOMA PROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; RNA, MESSENGER; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; TRANSCRIPTION FACTORS; UP-REGULATION;

EID: 3042841913     PISSN: 14345161     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10038-004-0146-3     Document Type: Article

References (40)

1. Buchkovich K, Duffy LA, Harlow E (1989) The retinoblastoma protein is phosphorylated during specific phases of the cell cycle. Cell 58:1097-1105
2. Chellappan SP, Hiebert S, Mudryj M, Horowitz JM, Nevins JR (1991) The E2F transcription factor is a cellular target for the RB protein. Cell 65:1053-1061
3. Chiappetta G, Toti P, Cetta F, Giuliano A, Pentimalli F, Amendola I, Lazzi S, Monaco M, Mazzuchelli L, Tosi P et al (2002) The RET/PTC oncogene is frequently activated in oncocytic thyroid tumors (Hurthle cell adenomas and carcinomas), but not in oncocytic hyperplastic lesions. J Clin Endocrinol Metab 87:364-369
4. Cloud JE, Rogers C, Reza TL, Ziebold U, Stone JR, Picard MH, Caron AM, Bronson RT, Lees JA (2002) Mutant mouse models reveal the relative roles of E2F1 and E2F3 in vivo. Mol Cell Biol 22:2663-2672
5. Dahia PL, Marsh DJ, Zheng Z, Zedenius J, Komminoth P, Frisk T, Wallin G, Parsons R, Longy M, Larsson C, Eng C (1997) Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res 57:4710-4713
6. DeCaprio JA, Ludlow JW, Lynch D, Furukawa Y, Griffin J, Piwnica-Worms H, Huang CM, Livingston DM (1989) The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element. Cell 58:1085-1095
7. DeGregori J, Leone G, Miron A, Jakoi L, Nevins JR (1997) Distinct roles for E2F proteins in cell growth control and apoptosis. Proc Natl Acad Sci USA 94:7245-7250
8. Dyson N (1998) The regulation of E2F by pRB-family proteins. Genes Dev 12:2245-2262
9. Flemington EK, Speck SH, Kaelin WG Jr (1993) E2F-1-mediated transactivation is inhibited by complex formation with the retinoblastoma susceptibility gene product. Proc Natl Acad Sci USA 90:6914-6918
10. Gaubatz S, Lindeman GJ, Ishida S, Jakoi L, Nevins JR, Livingston DM, Rempel RE (2000) E2F4 and E2F5 play an essential role in pocket protein-mediated G1 control. Mol Cell 6:729-735
11. Gorgoulis VG, Zacharatos P, Mariatos G, Kotsinas A, Bouda M, Kletsas D, Asimacopoulos PJ, Agnantis N, Kittas C, Papavassiliou AG (2002) Transcription factor E2F-1 acts as a growth-promoting factor and is associated with adverse prognosis in non-small cell lung carcinomas. J Pathol 198:142-156
12. Holm R, Nesland JM (1994) Retinoblastoma and p53 tumour suppressor gene protein expression in carcinomas of the thyroid gland. J Pathol 172:267-272
13. Humbert PO, Verona R, Trimarchi JM, Rogers C, Dandapani S, Lees JA (2000) E2f3 is critical for normal cellular proliferation. Genes Dev 14:690-703
14. Ikeda MA, Jakoi L, Nevins JR (1996) A unique role for the Rb protein in controlling E2F accumulation during cell growth and differentiation. Proc Natl Acad Sci USA 93:3215-3220
15. Johnson DG, Douglas Cress W, Jakioi L, Nevins JR (1994) Oncogenic capacity of the E2F1 gene. Proc Natl Acad Sci USA 91:12823-12827
16. Jones SJ, Dicker AJ, Dahler AL, Saunders NA (1997) E2F as a regulator of keratinocyte proliferation: implications for skin tumor development. J Invest Dermatol 109:187-193
17. Kovesdi I, Reichel R, Nevins JR (1987) Role of an adenovirus E2 promoter binding factor in E1A-mediated coordinate gene control. Proc Natl Acad Sci USA 84:2180-2184
18. La Perle KM, Jhiang SM, Capen CC (2000) Loss of p53 promotes anaplasia and local invasion in ret/PTC1-induced thyroid carcinomas. Am J Pathol 157:671-677
19. Lindeman GJ, Dagnino L, Gaubatz S, Xu Y, Bronson RT, Warren HB, Livingston DM (1998) A specific, nonproliferative role for E2F-5 in choroid plexus function revealed by gene targeting. Genes Dev 12:1092-1098
20. Lukas J, Petersen, BO, Holm K, Bartek J, Helin K (1996) Deregulated expression of E2F family members induces S-phase entry and overcomes p16INK4A-mediated growth suppression. Mol Cell Biol 16:1047-1057
21. Magnaghi-Jaulin L, Groisman R, Naguibneva I, Robin P, Lorain S, Le Villain JP, Troalen F, Trouche D, Harel-Bellan A (1998) Retinoblastoma protein represses transcription by recruiting a histone deacetylase. Nature 391:601-605
22. Moberg K, Starz MA, Lees JA (1996) E2F-4 switches from p130 to p107 and pRB in response to cell cycle reentry. Mol Cell Biol 16:1436-1449
23. Morkel M, Wenkel J, Bannister AJ, Kouzarides T, Hagemeier C (1997) An E2F-like repressor of transcription. Nature 390:567-568
24. Nevins JR (2001) The Rb/E2F pathway and cancer. Hum Mol Genet 10:699-703
25. Onda M, Nakamura I, Suzuki S, Takenoshita S, Brogren CH, Stampanoni S, Li D, Rampino N (2001) Microsatellite instability in thyroid cancer: hot spots, clinicopathological implications, and prognostic significance. Clin Cancer Res 7:3444-3449
26. Onda M, Li D, Suzuki S, Nakamura I, Takenoshita S, Brogren CH, Stampanoni S, Rampino N (2002) Expansion of micro-satellite in the thyroid hormone receptor-alpha1 gene linked to increased receptor expression and less aggressive thyroid cancer. Clin Cancer Res 8:2870-2874
27. Ono K, Tanaka T, Tsunoda T, Kitahara O, Kihara C, Okamoto A, Ochiai K, Takagi T, Nakamura Y (2000) Identification by cDNA microarray of genes involved in ovarian carcinogenesis. Cancer Res 60:5007-5011
28. Pan H, Yin C, Dyson NJ, Harlow E, Yamasaki L, Van Dyke T (1998) Key roles for E2F1 in signaling p53-dependent apoptosis and in cell division within developing tumors. Mol Cell 2:283-292
29. Pierce AM, Gimenz-Conti IB, Schneider-Broussard R, Martinez LA, Conti CJ, Johnson DG (1998) Increased E2F1 activity induces skin tumors in mice heterozygous and nullizygous for p53. Proc Natl Acad Sci USA 95:8858-8863
30. Puglisi F, Cesselli D, Damante G, Pellizzari L, Beltrami CA, Di Loreto C (2000) Expression of Pax-8, p53 and bcl-2 in human benign and malignant thyroid diseases. Anticancer Res 20:311-316
31. Saavedra HI, Wu L, de Bruin A, Timmers C, Rosol TJ, Weinstein M, Robinson ML, Leone G (2002) Specificity of E2F1, E2F2, and E2F3 in mediating phenotypes induced by loss of Rb. Cell Growth Differ 13:215-225
32. Saito M, Helin K, Valentine MB, Griffith BB, Willman CL, Harlow E, Look AT (1995) Amplification of the E2F1 transcription factor gene in the HEL erythroleukemia cell line. Genomics 25:130-138
33. Saiz AD, Olvera M, Rezk S, Florentine BA, McCourty A, Brynes RK (2002) Immunohistochemical expression of cyclin D1, E2F-1, and Ki-67 in benign and malignant thyroid lesions. J Pathol 198:157-162
34. Schlisio S, Halperin T, Vidal M, Nevins JR (2002) Interaction of YY1 with E2Fs, mediated by RYBP, provides a mechanism for specificity of E2F function. EMBO J 21:5775-5786
35. Tsai KY, Hu Y, Macleod KF, Crowley D, Yamasaki L, Jacks T (1998) Mutation of E2f-1 suppresses apoptosis and inappropriate S phase entry and extends survival of Rb-deficient mouse embryos. Mol Cell 2:293-304
36. Wiseman SM, Loree TR, Hicks WL Jr, Rigual NR, Winston JS, Tan D, Anderson GR, Stoler DL (2003) Anaplastic thyroid cancer evolved from papillary carcinoma: demonstration of anaplastic transformation by means of the inter-simple sequence repeat polymerase chain reaction. Arch Otolaryngol Head Neck Surg 129:96-100
37. Wyllie A (2002) E2F1 selects tumour cells for both life and death. J Pathol 198:139-141
38. Yamasaki L, Bronson R, Williams BO, Dyson NJ, Harlow E, Jacks T (1998) Loss of E2F-1 reduces tumorigenesis and extends the lifespan of Rbl((+/-)mice. Nat Genet 18:360-364
39. Zhang SY, Liu SC, Johnson DG, Klein-Szanto AJ (2000) E2F-1 gene transfer enhances invasiveness of human head and neck carcinoma cell lines. Cancer Res 60:5972-5976
40. Ziebold U, Reza T, Caron A, Lees JA (2001) E2F3 contributes both to the inappropriate proliferation and to the apoptosis arising in Rb mutant embryos. Genes Dev 15:386-391